Does Cigna cover Wegovy in 2026? Prior auth, step therapy, and appeal paths

What Cigna covers (a who's excluded)

Cigna's 2026 commercial obesity policy covers Wegovy for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity — hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease. The cardiovascular indication added in March 2024 follows separate criteria and opens coverage to a slightly different patient profile.

Two important exclusions catch people off-guard. First, self-funded employer plans on the Cigna network can opt out of obesity-drug coverage entirely — about 20-25% of Cigna-network self-funded plans do. Second, Cigna explicitly excludes coverage when Wegovy is sought solely for cosmetic weight loss, defined as use without medical necessity documentation. Practical effect: your prescriber's chart needs to document the comorbidity and medical necessity, not just BMI alone.

The 6-month lifestyle-attempt requirement

This is the criterion that produces the most denials. Cigna requires 6 months of documented lifestyle modification before initial Wegovy approval. Acceptable documentation includes structured weight-management program enrollment (Weight Watchers, Noom, hospital-based program), nutrition counseling visits, exercise-prescription records, or behavioral health counseling notes focused on weight management.

Two practical points. (1) Self-attested attempts ('I tried Atkins last year') don't qualify — Cigna wants contemporaneous documentation from a healthcare professional. (2) The 6 months can be cumulative, not consecutive. If you did 3 months of Noom in 2024 and 3 months of nutritionist visits in 2025, that counts as long as both are documented.

If you don't have 6 months of prior documentation, the simplest path is to start with your prescriber now: 6 months of monthly visits focused on lifestyle counseling, then submit. The Wegovy approval will come through after the 6-month window, but most patients consider this acceptable given the alternative is a multi-cycle appeal process.

Step-therapy: which medications must fail first

Cigna's preferred-agent list for obesity (subject to change by plan) typically includes phentermine (Adipex), naltrexone/bupropion (Contrave), and orlistat (Xenical). Liraglutide (Saxenda) is often listed as preferred over semaglutide on certain formularies because of cost differential. Step-therapy requires documented trial of at least one preferred agent with either failure (insufficient weight loss after appropriate trial duration) or intolerance (documented side effects requiring discontinuation).

Important: Saxenda failure can satisfy step therapy for Wegovy on most Cigna formularies because both are weight-management GLP-1 RAs. If you've tried Saxenda and discontinued for any reason, that history likely satisfies the step-therapy requirement and should be submitted with the initial PA. Many patients and prescribers miss this and default to the longer phentermine trial path.

The cardiovascular indication: a separate pathway

March 2024 brought a meaningful change. The FDA approved Wegovy for cardiovascular risk reduction based on the SELECT trial — adults with BMI ≥27 and established cardiovascular disease (prior MI, stroke, or peripheral artery disease). Cigna's coverage policy now includes this indication.

Critically, the cardiovascular indication does NOT require the 6-month lifestyle attempt OR step therapy. If you have established CV disease and meet the BMI threshold, your prescriber can submit under the cardiovascular indication a bypass the obesity-pathway requirements. Many prescribers and patients don't realize this exists. Documentation needed: history of MI, stroke, or peripheral artery disease confirmed via imaging or hospital record.

The appeal playbook when denied

First denial typically arrives within 5-7 days. Read the denial letter carefully — Cigna will cite the specific criterion that wasn't met. Most denials are NOT 'not medically necessary' but rather 'incomplete documentation' (missing 6-month lifestyle attempt records, missing comorbidity confirmation, missing step-therapy trial). The fix is documentation, not appeal.

If documentation is complete and the denial stands, the first-level appeal must be filed within 180 days. Send and letter of medical necessity citing the specific Cigna policy, your BMI, your comorbidities (with lab values or imaging if relevant), and documentation of prior attempts. Include and statement signed by your prescriber explaining medical necessity in their words.

If first appeal fails, request peer-to-peer review where your prescriber speaks with Cigna's medical director by phone. This bypasses chart review and often resolves denials based on documentation gaps. If still denied, ERISA-governed plans (most employer plans) allow external independent review — and third-party reviewer makes a binding determination. External review wins about 50-60% of well-documented obesity-drug appeals.

Cost when covered

On Cigna commercial plans, Wegovy is typically Tier 2 (preferred brand) or Tier 3 (non-preferred brand). Tier 2 copays on a standard 30-day supply are commonly $40-80; Tier 3 can be $80-150 or coinsurance-based (20-40% of plan cost). Specialty-tier placement (Tier 4) is rare for Wegovy on Cigna but can occur on tightly-managed formularies.

Stack savings: Novo Nordisk's Wegovy savings card brings the copay to as low as $25/month for patients with commercial insurance (regardless of carrier). Eligibility excludes Medicare and Medicaid recipients. Use the savings card in conjunction with the insurance copay — the card pays the difference up to a monthly cap.